Abstract 4701
Background
Non-squamous non-small cell lung cancer (NSCLC) accounts for majority of lung cancer, the second most common cancer in US. Combination of checkpoint inhibitors and chemotherapy has become a fundamental paradigm shift in the first-line treatment of advanced lung cancer. We conducted a combined analysis of randomized controlled trials (RCT) to determine the risk of treatment-related adverse events (TRAE) and treatment discontinuation due to TRAE.
Methods
PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. RCTs of first-line chemotherapy +/- immunotherapy in patients with advanced non-squamous NSCLC were incorporated. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) and risk difference (RD) with 95% confidence interval (CI). Random effects model was applied.
Results
A total of 2785 patients with advanced non-squamous NSCLC from 5 RCTs were included. The study arm used standard chemotherapy regimens in combination with pembrolizumab or atezolizumab while control arm used only standard chemotherapy regimens. The randomization ratio was 2:1 in IMpower-130 and Keynote-189 studies and 1:1 in other studies. The pooled RR of any-grade TRAE was 1.02 (95% CI: 0.99 –1.04, P = 0.20) and RR of high-grade TRAE was significant at 1.20 (95% CI: 1.07 –1.34, P = 0.002). Treatment-related deaths were 58 (3.57%) in study arm vs 31 (2.66%) in control arm. The pooled RR was not statistically significant at 1.26 (95% CI: 0.81 –1.95, P = 0.31) and RD was 0.01 (95% CI: - 0.00 – 0.02, P = 0.08). Treatment discontinuation due to TRAE was noted in 440 (27.14%) vs 235 (20.19%) in control group with RR of 1.35 (95% CI: 1.15 –1.59, P = 0.0003) and RD of 0.07 (95% CI: 0.03 – 0.11, P = 0.001).
Conclusions
Patients on upfront combined chemoimmunotherapy experienced high-grade TRAE, ultimately leading to treatment discontinuation. Yet, there were no significant increase in the risk of treatment related deaths due to TRAE, compared to standard chemotherapy. Pre-emptive measures with proper supportive care may enhance patients’ quality of life and compliance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kyaw Zin Thein.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract